1 |
Company report (PaxVax)
|
2 |
Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92.
|
3 |
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92.
|
4 |
Clinical pipeline report, company report or official report of Roche.
|
5 |
Clinical pipeline report, company report or official report of Visterra.
|
6 |
An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94.
|
7 |
Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
|
8 |
A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989.
|
9 |
Clinical pipeline report, company report or official report of Vir Biotechnology.
|
10 |
How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
|
11 |
Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
|
|
|
|
|
|
|